Stocks · News reference
Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates. HC Wainwright & Co raised its price target on the stock from $95 to $115.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 11:24 AM
- Checked
- Aug 7, 2026, 11:24 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — HALOZYME THERAPEUTICS, INC. (HALO)
Filed: 2026-08-18 AccNo: 0001159036-26-000106 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarWatching Halozyme Therapeutics; Hearing Investor Business Daily SwingTrader Buys Stock
Read original at benzingaTop 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Read original at benzinga